$AXON

SMITH PATRICK W sold $5.0M of AXON

SMITH PATRICK W (CHIEF EXECUTIVE OFFICER) sold 10,000 shares of AXON ENTERPRISE, INC. (AXON) at $500.00 ($5.00M total) on 2026-06-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · SMITH PATRICK W
Published Jun 30, 2026, 8:58 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 30, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$AXON
Neutral
medium confidence
Mentioned
$AXON
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AXONNeutralLow
01

Why it matters

The CEO’s open-market sale is disclosed with a stated 10b5-1 pre-arranged plan, which generally lowers informational content about near-term business risk.

02

Market read

This is a disclosed insider sale; it may cause brief sentiment noise but is unlikely to drive a fundamental repricing by itself.

03

What to watch

Traders may still watch for follow-on insider activity (additional sales/buys) or whether the sale size is unusual relative to prior Form 4 patterns, which are not provided here.

Relevance 5/10Novelty 5/10Timing: after-hours/filing timestamp (2026-06-30) for a 2026-06-29 sale disclosure

Background

The article is an SEC Form 4 insider transaction disclosure for Axon Enterprise, Inc.

Company-level read

Ticker impact

$AXONNeutralMedium confidence
Context

Axon CEO Smith Patrick W filed a Form 4 open-market sale of 10,000 shares at ~$500.0018 on 2026-06-29 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this Form 4; any impact would be sentiment-driven and short-lived.

Evidence & confidence

The filing is a disclosed insider transaction with a pre-arranged 10b5-1 plan, which reduces the probability the sale reflects new negative information.

Market effects

Minimal; insider selling at a single company does not materially reset sector fundamentals.

Minimal; no broader regional catalyst indicated.

Minimal; transaction is company-specific and not tied to global events.

Counterpoint

Because it’s a 10b5-1 plan, the sale may be purely mechanical (tax/liquidity) and should not be over-weighted versus operating fundamentals.

Key entities

  • AXON

    Axon Enterprise, Inc., issuer of the Form 4 insider transaction.

  • SMITH PATRICK W

    Chief Executive Officer and director who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AXONMedAI 8/10

Axon’s AI Era Revenue Jumped Nearly 700%. Here’s What’s Behind It

Axon Enterprise (AXON) reported 35% revenue growth to $904M, beating estimates. AI Era revenue surged nearly 700% YoY. Management raised full-year guidance to 32-34% growth. Gross margin slipped 40 basis points to 62.9%. Analysts estimate a target price of $714, implying 13.7% upside over 2.4 years. The stock trades at 70x forward earnings, with growth driven by software and AI products.

$BABAHighAI 8/10

Breakfast News: Alibaba's AI Push Comes at a Cost

Alibaba's Q1 revenue rose 9% to $39.6B, but operating income fell 57% due to tech investments. BILL Holdings reported 14% revenue growth and 80% operating income increase. U.S. debt surpassed $40T, with Treasury buybacks easing yield pressure. Apple plans 2027 launch for camera AirPods. Axon Enterprise passes competitive position tests, with a 69% potential upside to $1,088.08.

$AXONMed

Axon Stock Rebounds As Its Margin Squeeze Looks Like The Price Of Growth

Axon Enterprise (AXON) shares rose 9.3% on Friday after a 14.3% drop the prior session following its Q2 2026 results. The quarter showed revenue of $904 million, up 35% year over year, and a raised full-year outlook. The market disagreed over margin compression tied to higher memory costs and counter-drone hardware mix, with Axon expecting Q3 adjusted EBITDA margin to hold and rebuild in Q4.

$AXONMed

Raise. So Why Is the Stock Down?

Axon Enterprise (NASDAQ: AXON) reported Q2 revenue of $904M, up 35% year over year, beating estimates of $876.5M. Adjusted EBITDA rose 40% to $242M, and adjusted EPS was $1.88 vs $1.84 expected. Axon raised full-year revenue guidance to 32%-34% growth but reduced software and services gross margin and withdrew operating cash flow and free cash flow guidance.